An
angiotensin 2 type 1 receptor blocker (ARB)
telmisartan possesses not only an
anti-hypertensive effect but also an anti-
metabolic syndrome effect due to
peroxisome proliferator-activated receptor γ (
PPAR-γ) activation. In the present study, we examined the effects of
telmisartan on the
angiotensin 2 type 1 receptor (AT1R),
PPAR-γ, and
insulin receptor (IR) in
stroke-resistant spontaneously hypertensive rats (SHR-SR), comparing them with Wistar rats. Three-months-old SHR-SR rats were divided into three treatment groups, i.e., vehicle (SHR/Ve), low-dose
telmisartan (0.3 mg/kg/day, SHR/Low), and high-dose
telmisartan (3 mg/kg/day, SHR/High). Compared with Wistar rats, SHR/Ve increased the staining of AT1R,
PPAR-γ and IR in the cerebral cortical neurons. On the other hand,
telmisartan dose-dependently suppressed the excessive expression of AT1R and IR, but enhanced
PPAR-γ activation. Low-dose
telmisartan showed these effects even without lowering blood pressure (BP), while high-dose
telmisartan lowered BP and showed further effects. The present study suggests that even a low dose of
telmisartan decreased AT1R and IR, and increased
PPAR-γ in the cerebral cortex of SHR-SR without lowering BP, probably by improving
glucose homeostasis. The high dose of
telmisartan showed further decreases in AT1R and IR, and further
PPAR-γ activation while lowering BP, suggesting an additive benefit to lowering BP, namely the improvement of
glucose homeostasis.